EP1066311A4 - Zusammensetzungen und methoden zur identifizierung von lungentumorzellen - Google Patents

Zusammensetzungen und methoden zur identifizierung von lungentumorzellen

Info

Publication number
EP1066311A4
EP1066311A4 EP99914285A EP99914285A EP1066311A4 EP 1066311 A4 EP1066311 A4 EP 1066311A4 EP 99914285 A EP99914285 A EP 99914285A EP 99914285 A EP99914285 A EP 99914285A EP 1066311 A4 EP1066311 A4 EP 1066311A4
Authority
EP
European Patent Office
Prior art keywords
compositions
identification
methods
tumor cells
lung tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99914285A
Other languages
English (en)
French (fr)
Other versions
EP1066311A1 (de
Inventor
Gary A Beaudry
Stephen L Madden
Arthur H Bertelsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to EP06026756A priority Critical patent/EP1790717A3/de
Priority to EP03002096A priority patent/EP1310556A3/de
Publication of EP1066311A1 publication Critical patent/EP1066311A1/de
Publication of EP1066311A4 publication Critical patent/EP1066311A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP99914285A 1998-03-31 1999-03-30 Zusammensetzungen und methoden zur identifizierung von lungentumorzellen Withdrawn EP1066311A4 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06026756A EP1790717A3 (de) 1998-03-31 1999-03-30 Zusammensetzungen und Verfahren zur Identifizierung von Lungentumorzellen
EP03002096A EP1310556A3 (de) 1998-03-31 1999-03-30 Zusammensetzungen und Methoden zur Identifizierung von Lungentumorzellen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8003798P 1998-03-31 1998-03-31
US80037P 1998-03-31
PCT/US1999/006938 WO1999050278A1 (en) 1998-03-31 1999-03-30 Compositions and methods for the identification of lung tumor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP03002096A Division EP1310556A3 (de) 1998-03-31 1999-03-30 Zusammensetzungen und Methoden zur Identifizierung von Lungentumorzellen

Publications (2)

Publication Number Publication Date
EP1066311A1 EP1066311A1 (de) 2001-01-10
EP1066311A4 true EP1066311A4 (de) 2002-04-10

Family

ID=22154860

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99914285A Withdrawn EP1066311A4 (de) 1998-03-31 1999-03-30 Zusammensetzungen und methoden zur identifizierung von lungentumorzellen

Country Status (5)

Country Link
EP (1) EP1066311A4 (de)
JP (1) JP2002509707A (de)
AU (1) AU757478C (de)
CA (1) CA2323833A1 (de)
WO (1) WO1999050278A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE546544T1 (de) 1998-03-31 2012-03-15 Esoterix Genetic Lab Llc Verfahren zur diagnose und behandlung von lungenkrebs
AU2001251084A1 (en) * 2000-03-29 2001-10-08 Diadexus, Inc. Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
AU2001264559A1 (en) * 2000-06-05 2001-12-17 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
ATE449187T1 (de) * 2001-08-16 2009-12-15 Us Health Molekulare eigenschaften von nichtkleinzelligem lungenkrebs
WO2003040317A2 (en) * 2001-11-02 2003-05-15 Pfizer Products Inc. Lung cancer therapeutics and diagnostics
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042211A1 (en) * 1996-05-06 1997-11-13 Chiron Corporation Mammalian sex comb on midleg (mammalian scm) acts as a tumor suppressor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE168135T1 (de) * 1988-01-21 1998-07-15 Massachusetts Eye & Ear Infirm Diagnose von retinoblastoma
JPH03503843A (ja) * 1988-04-15 1991-08-29 バイオジェン インコーポレイテッド ホスホリパーゼａ２の精製方法およびホスホリパーゼａ２様ポリペプチドの製造方法
US5919649A (en) * 1988-11-18 1999-07-06 The General Hospital Corporation Camp-responsive transcriptional enhancer binding protein
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042211A1 (en) * 1996-05-06 1997-11-13 Chiron Corporation Mammalian sex comb on midleg (mammalian scm) acts as a tumor suppressor

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BACHER N ET AL.: "Isolation and characterzation of PKC-L, a new member of the protein kinase C-related gene family specifically expressed in lung, skin and heart.", MOLECULAR CELL BIOLOGY, vol. 11, no. 1, January 1991 (1991-01-01), XP001032543 *
BIRRER MJ AND BROWN PH: "Application of molecular genetics to the early diagnosis and screening of lung cancer", CANCER RESEARCH., vol. 52, no. suppl, 1 May 1992 (1992-05-01), AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, pages 2658s - 2664s, XP002180205, ISSN: 0008-5472 *
DATABASE GENBANK E.B.I. Hinxton U.K.; 17 February 1997 (1997-02-17), ZSCHUNKE F: "Serine Esterase", XP002179576 *
DATABASE GENBANK E.B.I. Hinxton U.K.; 18 May 1994 (1994-05-18), HALLEWELL RA: "Mouse Manganese Superoxide Dismutase", XP002179578 *
DATABASE GENBANK E.B.I. Hinxton, U.K.; 27 April 1993 (1993-04-27), LONG RM: "Human Liver Carboxylesterase isoezyme", XP002179577 *
SALGIA R AND SKARIN AT: "Molecular abnormalities in lung cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. 16, no. 3, March 1998 (1998-03-01), PHILADELPHIA, PA, US, pages 1207 - 1217, XP001030483 *
See also references of WO9950278A1 *
VAN ZANDWIJK N AND VAN 'T VEER L: "The role of prognostic factors and oncogenes in the detection and management of Non-Small-Cell Lung Cancer", ONCOLOGY., vol. Supplement 2, January 1998 (1998-01-01), S. KARGER AG, BASEL., CH, pages 55 - 59, XP001031838, ISSN: 0030-2414 *

Also Published As

Publication number Publication date
CA2323833A1 (en) 1999-10-07
AU3216899A (en) 1999-10-18
WO1999050278A1 (en) 1999-10-07
JP2002509707A (ja) 2002-04-02
AU757478C (en) 2004-03-25
EP1066311A1 (de) 2001-01-10
AU757478B2 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
AU2212299A (en) Compositions and methods for the treatment of tumor
AU3905399A (en) Methods and compositions for transgene identification
PL354093A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
IL139247A0 (en) Hematopoietic stimulation
HUP0100765A3 (en) Composition for the treatment of halitosis
IL141403A0 (en) Deleted adenoviruses and methods of making and administering the same
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
GB2361996B (en) Multiple marker characterization of single cells
EP1119365A4 (de) Zusammensetzung und methode zur verwendung von tumorzellen
AP2000002010A0 (en) Novel pharmaceutical compositions for treating and saving and the methods for the preparation thereof
EP1056456A4 (de) R-lansoprazol zusammenstellungen und behandlungen damit
HK1039495A1 (en) Propylene homopolymers and methods of making the same
IL145520A0 (en) Flame-retarding composition and process for the preparation thereof
ZA200006300B (en) Composition comprising tumor cells and extracts and method of using thereof.
ZA954984B (en) Compositions and methods for the treatment of tumors
IL143212A0 (en) Compositions and methods for the treatment of tumor
IL141426A0 (en) Compositions and methods for the treatment of tumor
EP1073333A4 (de) S-rabeprazol enthaltende zusammensetzungen und verfahren
EP1066311A4 (de) Zusammensetzungen und methoden zur identifizierung von lungentumorzellen
EP1080225A4 (de) Zusammensetzungen und methoden zur pulmonalen verabreichung von nukleinsäuren
EP1139981A4 (de) Zusammentsetzungen und verfahren zu ihrer verwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020225

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020530

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030503